DMAC vs GILD · $157.4M cap vs P/E 18, rev $29.44B
DiaMedica Therapeutics Inc (DMAC) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
DMAC currently screens at market cap $157.4M. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the DMAC and GILD stock pages for the full models.
Not investment advice.